FDA expands Anktiva approval for BCG-unresponsive bladder cancer. Learn about the 62% trial response, eligible patients, ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ANKTIVA® ...
Highlights15-10 Source Well - located on the Initial Production Module ("IPM") pad - intersected 20.5m of net sylvinite grading 39.4% sylvite (KCl);Belle Plaine Member at 15-10 - the Member hosting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results